Answers are grounded in this paper and cite their sources.
Pharmacogenomics (PGx) demonstrates how inherited genetic variation can influence drug metabolism, exposure and response, but its application in forensic toxicology remains comparatively underdeveloped. This review examines how clinical pharmacogenomic knowledge may be translated into postmortem toxicological interpretation, particularly where measured drug concentrations do not fully explain the circumstances of death. Conventional interpretation is complicated by interindividual variability, postmortem redistribution, tolerance, polypharmacy and drug interactions. Genetic variation affecting pharmacogenes, particularly CYP450 enzymes, may contribute to altered parent-drug and metabolite concentrations and help explain unexpected toxicity or concentration patterns. However, genotype does not necessarily reflect functional metabolic activity because co-administered drugs, disease and environmental influences can produce phenoconversion. Drug–drug–gene interactions must therefore be considered alongside genetic findings. Practical implementation is additionally constrained by specimen quality, analytical and interpretative requirements, and the absence of standardised forensic-specific guidelines. Guidance on specimen collection and preservation, alongside emerging molecular and computational approaches, may support more reliable testing and individualised interpretation. PGx should not independently determine cause or manner of death, but may provide complementary information when integrated with toxicology, pathology, medical and prescription history, scene findings and postmortem factors.
No takes yet. Share an insight, caveat, or question.
Jobi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: